Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The 60-year-old sports fan, a surgeon who started and sold two pharmaceutical companies for a combined $8.6 billion, told Reuters in an interview this week that he wants to use Anschutz concert tours and sports events, and his NFL team’s players, to encourage L.A. school children to adopt healthier lifestyles. “The NFL can do so much for this city,” said Soon-Shiong in an interview at his west Los Angeles office. “Kids really rally around sports and entertainment and it could be a major catalyst to demonstrate what you can do in life by living better.”  Soon-Shiong grew up in South Africa, where he became a doctor in his early 20s and treated tuberculosis victims. After moving to the United States and becoming a surgeon at UCLA, he developed innovative methods to treat diabetes and cancer patients. The sale of his two companies for $8.6 billion made him the wealthiest person in Los Angeles, according to Forbes magazine, although he still is not a household name in the city. Under his plan, players would serve as mentors, encouraging students to eat better and exercise more. The most sophisticated methods used to deal with sports injuries could be shared with local doctors. “It’s important to motivate students in middle and high school. That’s when you can help reduce diabetes and obesity that cause illness,” he said. “Maybe we can turn that illness to wellness.”  If he’s successful in L.A., Soon-Shiong said he intends to make it a national program. Sources say the billionaire is assembling a group of other Los Angeles business and civic leaders to buy AEG. Soon-Shiong did not discuss details of his bid. Sources also said his buyer group includes private equity firm Guggenheim Partners, which this spring led a group that bought the Los Angeles Dodgers baseball team for $2 billion. AEG, which is owned by Denver billionaire Phil Anschutz, said on September 19 it had hired Blackstone Advisory Partners to sell the company. It is expected to fetch $6 billion to $8 billion, according to investment bankers with knowledge of its assets. Separately, Los Angeles for years has wanted to bring back a professional football team, and Soon-Shiong acknowledged that he has met with the NFL to lay out his plan to buy a team. AEG owns the Los Angeles Kings pro hockey franchise, the L.A. Galaxy soccer club and a 20 percent stake in the Los Angeles Lakers basketball team. It owns or operates sports and entertainment arenas worldwide, including the Staples Center in Los Angeles, and promotes concerts and other live action events. Soon-Shiong’s family foundation has committed $1 billion to transform healthcare and intends to create a national health superhighway by which doctors can share biotech information and other data to improve diagnosis and care. His foundation gave $135 million to the Saint John’s Health Center in Santa Monica and $100 million to reopen Martin Luther King Hospital, which serves lower income patients in south Los Angeles. A basketball fan who played in pickup games until tearing his Achilles tendon three years ago, Soon-Shiong owns a 5 percent stake in the Lakers, and he said he has become friends with superstar Kobe Bryant and other players, whom he sees as role models for young fans. In March, he and his actress wife, Michelle Chan, endowed the Chan Soon-Shiong Center for Sports Science at Saint John’s, which will focus on sports medicine, physical therapy and stem cell research to help heal injuries. It works with sports medicine doctors, including the Kerlan-Jobe Orthopedic Clinic that treats the Kings, Lakers and L.A. Dodgers. Saint John’s announced the sports science center at a dinner honoring AEG president Tim Leiweke in March, six months before Soon-Shiong showed his interest in the conglomerate. Claim: LA billionaire covets sports teams to promote health.

A: Bio-tech entrepreneur Patrick Soon-Shiong, the richest man in Los Angeles, intends to make a bid for sports and real estate firm Anschutz Entertainment Group and wants to bring a National Football League team back to the second most populous U.S. city.
****
Q: Paragraph: A photograph popped up on social media in May 2015, described as a picture of a blood clot removed from an 80-year-old patient after he presented with a 2-day-long nosebleed. According to the accompanying text, the patient coded shortly after arrival at an emergency room, and a blood clot that went “from his nose down his airway and into his lungs” was removed via intubation:  80 yr old male with nose bleed for 2 days. Refused to go to ER. Wife finally talked husband to go to ER. He coded shortly after arriving. Medical doctor went to do intubation and found this. Pulled it out in one piece. It a blood clot that goes from his nose down his airway and into his lungs. It an amazingly beautiful blood clot. The photograph was shared by Kevin Kimberlin, an EMT who told us that the patient was treated at a hospital he transports to and that he picture was taken by a friend of his who worked on the patient. In November 2018, the New England Journal of Medicine website posted a similar photograph of “an intact cast of the right bronchial tree” that was “spontaneously expectorated” by a patient “during an extreme bout of coughing”: Claim: A photograph shows a large blood clot removed from a patient's lung.

A: A photograph purportedly captured a huge blood clot removed from a patient's lung.
****
Q: Paragraph: The ruling will likely offer some respite to the healthcare conglomerate as it deals with growing pressure over the safety of its talc products, some defense lawyers said. The company revealed in its annual report on Wednesday that it had received subpoenas from the U.S. Justice Department and the Securities and Exchange Commission related to talc litigation. Some plaintiffs’ lawyers, however, played down the impact of the ruling. It was a trial in St. Louis’s 22nd Circuit Court, brought by 21 plaintiffs from outside of the city whose cases were joined to that of a single St. Louis resident, that in July produced a record $4.69 billion talc verdict against J&J. The company is facing several more such lawsuits in St. Louis. However, Missouri’s high court on Feb. 13 ruled in a separate talc case that allowed a non-resident to participate in joined cases was “a clear and direct violation” of state law barring the use of joinder - combining two or more cases - to allow courts to hear cases they otherwise could not. Most state courts can only hear cases involving plaintiffs or defendants from that state or alleging injuries occurring within their jurisdiction. The U.S. Supreme Court strengthened those restrictions in a 2017 decision. But the St. Louis court had allowed out-of-state residents to continue to sue New Jersey-based J&J through liberal use of joinder. In the case that produced the July verdict, 18 of the plaintiffs were from outside Missouri and three were from outside the city of St. Louis. Of the roughly 700 talc cases filed in St. Louis, only 40 involve Missouri residents, according to court filings. If the Feb. 13 ruling closes off the St. Louis court to non-resident claims, J&J may have a stronger hand defending itself in smaller talc cases spread out among other, potentially less plaintiff-friendly state and federal courts. “There’s no real way of reading this decision other than this court clearly saying you can’t join claims if the injury did not occur in the venue,” said Mark Cheffo, a New York-based product liability defense lawyer not involved in talc litigation. J&J in a statement said it was pleased with the decision. “One claim that is properly before a court cannot provide a basis for drawing into a trial other claims that are not. We believe that decision is clearly correct, and we continue to believe that the science doesn’t support plaintiffs’ claims,” the company said, declining further comment. Some plaintiffs’ lawyers said the Feb. 13 ruling was not as definitive as Cheffo suggests. “If defendants are celebrating this ruling as the end of St. Louis mass tort, they have not read the entire Missouri case law,” said Eric Holland, a St. Louis-based plaintiff lawyer involved in the talc litigation. Holland pointed to a 2016 Missouri Supreme Court decision that upheld a $38 million verdict in a pharmaceutical product liability case the defendant claimed had been improperly joined. The court let the result stand, saying that even an improper joinder did not render the trial unfair to defendants. Though the 2016 ruling involved a case already decided, Holland and other plaintiffs’ lawyers said they planned to argue its fairness analysis also applies to out-of-state talc claims in cases yet to go to trial. They said they would also argue joining the cases was the most efficient use of judicial resources. Defense lawyers said the Feb. 13 decision would likely mean dismissal or severing of the out-of-state claims from four upcoming multi-plaintiff cases scheduled for trial in St. Louis. Two of the cases were halted by the Missouri Supreme Court ahead of its ruling. Holland and other plaintiff lawyers said they would challenge J&J requests to sever or dismiss talc cases by arguing the Feb. 13 decision did not overrule the 2016 ruling. Cheffo said the 2016 ruling could make it harder for J&J to overturn the July verdict and its record penalty because the company would have to prove the joinder led to an unfair trial. ‘FORUM SHOPPING’ BY OUT-OF-STATE PLAINTIFFS  The St. Louis court has been a venue for more talc trials and has seen larger verdicts than any other jurisdiction. Outside of St. Louis, the only other significant talc verdicts against J&J to date have come in lawsuits filed by individual plaintiffs in New Jersey and California, where the company is currently facing jury verdicts totaling $142 million. A Los Angeles jury delivered a $417 million talc verdict against J&J in 2017, but the judge threw out the award weeks later as unsupported by the evidence. All talc verdicts against J&J are on appeal. The St. Louis court has a history of issuing large punitive damages against companies and has often been criticized by business groups as allowing “forum-shopping” by out-of-state plaintiffs. While J&J faces some trials brought by individuals in other jurisdictions, the multi-plaintiff St. Louis cases are the largest and have the most potential to produce additional billion-dollar verdicts. Plaintiffs allege that the talc in Johnson’s baby powder and other J&J products causes ovarian cancer, or that asbestos contamination in the talc causes ovarian cancer and mesothelioma. Asbestos is a known carcinogen linked to mesothelioma. J&J and its talc supplier, Imerys Talc America, a co-defendant in the litigation, deny the allegations, saying numerous studies and tests by regulators worldwide have shown their talc to be safe and asbestos-free. Reuters on Dec. 14 published a report detailing that J&J knew that the talc in its raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s - test results it did not disclose to regulators or consumers. (reut.rs/2Gh88KO)   J&J is currently facing roughly 13,000 lawsuits over talc, most of which have been consolidated in federal court in New Jersey. Many plaintiff’s lawyers have fought to keep cases out of federal court, which they feel favors corporate defendants. Three juries have rejected claims that Baby Powder was tainted with asbestos or caused plaintiffs’ mesothelioma. Five other juries have failed to reach verdicts, resulting in mistrials. In a statement, Imerys Talc America said the Missouri ruling affirmed legal arguments it has made in litigation for the last four years. The company filed for Chapter 11 bankruptcy on Feb. 13, saying it lacked the financial clout to defend against talc lawsuits. Claim: Court ruling could help J&J defeat St. Louis talc lawsuits.

A:
A Missouri Supreme Court ruling on talc lawsuits could reduce the liability and number of large trials Johnson & Johnson faces over allegations its talc products, including baby powder, cause cancer.
****